EUCTR2010-022793-14-FR进行中（未招募）1 期
A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate the efficacy and safety of masitinib in combination with 5-fluorouracil (5-FU) or capecitabine, or masitinib in combination with irinotecan, or masitinib in combination with irinotecan, 5-fluorouracil (5-FU) and folinic acid (FOLFIRI protocol), as second line chemotherapy in patients with gastric or gastro-oesophageal junction metastatic adenocarcinoma.
AB Science0 个研究点目标入组 57 人开始时间: 2010年11月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 57
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Patient with histologically or cytologically advanced-stage, recurrent adenocarcinoma of the stomach or gastro-oesophageal junction (unresectable, and/or metastatic)
- •2. Patient has failed to one prior cycle cancer therapy (radiotherapy, chemotherapy or chemoradiotherapy) given > 4 weeks prior to baseline. Failure is defined either by progression of disease or by significant toxicity that precludes further treatment.
- •3. Patient has recovered of all acute toxic side effects of prior therapy or surgical procedures to grade = 1 National Cancer Institute-Common Toxicity Criteria (NCI-CTCAE v4.02), except for the laboratory values
- •4. Patient is at least 4 weeks from any major surgery (at baseline)
- •5. Patient is eligible for a second line treatment with 5-fluorouracil (5-FU) or capecitabine, or irinotecan, or irinotecan, 5-fluorouracil (5-FU) and folinic acid (FOLFIRI protocol)
- •6. Patient has at least one untreated target lesion that could be measured in one dimension, according to the Response Evaluation Criteria in Solid Tumors (RECIST).
- •7. ECOG Performance status = 2
- •8. Patient with Karnofsky Performance Status (KPS) = 70
- •9. Patient with adequate organ function:
- •Absolute Neutrophil Count (ANC) = 1.5 x 109/L
- •Haemoglobin = 10 g/dL
- •Platelets (PTL) = 100 x 109/L
- •AST/ALT = 5 x ULN
- •Gamma-GT = 5 x ULN
- •Bilirubin = 3x ULN
- •Creatinin clearance = 50 mL/min (Cockcroft and Gault formula)
- •Albumin > LLN
- •Urea = 2 x ULN
- •Proteinuria < 30 mg/dL; in case of proteinuria = 30 mg/dL on the dipstick, 24 hours proteinuria < 1.5g/24 hours
- •10. Male or female = 18 years
- •11. Patient with life expectancy = 6 months
- •12. Patient weight > 40 kg and BMI > 18
- •13. Man and woman who childbearing potential (entering the study after a menstrual period and who have a negative pregnancy test), agrees to use two methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for 3 months after the last treatment intake.
- •14. Patient is able and willing to comply with study visits and procedures as per protocol
- •15. Patient is able to understand, sign, and date the written informed consent form at the screening visit prior to any protocol-specific procedures performed
- •16. Patient affiliated to a social security regimen
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A patient must not be enrolled if he/she fulfils one of the following exclusion criteria:
- •1.Patient intolerant to 5-fluorouracil (5-FU) or capecitabine or irinotecan or FOLFIRI protocol
- •2.Patient previously treated with more than one prior systemic regimen for the treatment of gastric cancer including chemotherapy and targeted anticancer therapy (including masitinib and other Tyrosine Kinase inhibitors)
- •3.Patient who had systemic chemotherapy within 4 weeks before baseline
- •4.Patient who had radiotherapy within 4 weeks before baseline
- •5.Patient who had major surgery within 4 weeks before the start of study treatment (laparotomy, line placement is not considered major surgery)
- •6.Patient who had have not recovered from prior treatments
- •7.Patient presenting with cardiac disorders defined by at least one of the following conditions:
- •Patient with recent cardiac history (within 6 months) of:
- •-Acute coronary syndrome
- •-Acute heart failure (class III or IV of the NYHA classification)
- •-Significant ventricular arrhythmia (persistent ventricular tachycardia, ventricular fibrillation, resuscitated sudden death)
- •Patient with cardiac failure class III or IV of the NYHA classification
- •Patient with severe conduction disorders which are not prevented by permanent pacing (atrio-ventricular block 2 and 3, sino-atrial block)
- •Syncope without known aetiology within 3 months
- •Uncontrolled severe hypertension, according to the judgment of the investigator, or symptomatic hypertension
- •8.Pregnant or nursing female patient
- •9.Patient presenting at least a grade II peripheral neuropathy
- •10.Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis
- •11.Patient with history of poor compliance or history of drug/alcohol abuse, or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent
- •Previous treatment
- •12.Patient treated with any investigational agent within 4 weeks prior baseline
研究者
相似试验
进行中（未招募）
1 期
Evaluation of safety and efficacy of masitinib combined with etoposide or irinotecan in patients with relapsing liver cancerMedDRA version: 18.1 Level: LLT Classification code 10019829 Term: Hepatocellular carcinoma recurrent System Organ Class: 100000004864MedDRA version: 18.1 Level: LLT Classification code 10019828 Term: Hepatocellular carcinoma non-resectable System Organ Class: 100000004864MedDRA version: 18.1 Level: LLT Classification code 10019830 Term: Hepatocellular carcinoma resectable System Organ Class: 100000004864Hepatocellular carcinomaEUCTR2010-022620-77-GRAB Science34
进行中（未招募）
1 期
Evaluation of safety and efficacy of masitinib combined with etoposide or irinotecan in patients with relapsing liver cancerHepatocellular carcinomaMedDRA version: 17.1 Level: LLT Classification code 10019829 Term: Hepatocellular carcinoma recurrent System Organ Class: 100000004864MedDRA version: 17.1 Level: LLT Classification code 10019828 Term: Hepatocellular carcinoma non-resectable System Organ Class: 100000004864MedDRA version: 17.1 Level: LLT Classification code 10019830 Term: Hepatocellular carcinoma resectable System Organ Class: 100000004864EUCTR2010-022620-77-SKAB Science36
进行中（未招募）
1 期
A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate efficacy and safety of masitinib in combination with etoposide, or masitinib in combination with irinotecan in patients with advanced hepatocellular carcinoma and who relapsed after a first line therapy with sorafenib.MedDRA version: 12.1 Level: LLT Classification code 10019830 Term: Hepatocellular carcinoma resectableMedDRA version: 12.1 Level: LLT Classification code 10019828 Term: Hepatocellular carcinoma non-resectableMedDRA version: 12.1 Level: LLT Classification code 10019829 Term: Hepatocellular carcinoma recurrenthepatocellular carcinomaEUCTR2010-022620-77-FRAB Science36
进行中（未招募）
1 期
Evaluation of safety and efficacy of masitinib combined with etoposide or irinotecan in patients with relapsing liver cancerMedDRA version: 20.0Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10019830Term: Hepatocellular carcinoma resectableSystem Organ Class: 100000004864Hepatocellular carcinomaEUCTR2010-022620-77-CZAB Science36
进行中（未招募）
1 期
Evaluation of safety and efficacy of masitinib combined with etoposide or irinotecan in patients with relapsing liver cancerHepatocellular carcinomaEUCTR2010-022620-77-ESAB Science36